Andrew Schwab, Director, Ten Percent Owner at Skye Bioscience, holds 981.27K shares in Skye Bioscience (Ticker: SKYE), holds 5.28M shares in CAMP4 Therapeutics Corporation (Ticker: CAMP), holds 960.38K shares in Enliven Therapeutics (Ticker: ELVN). Most recently, Andrew Schwab Sold ― shares of Skye Bioscience on Sep 24, 2026 for an estimated value of $239.56K.
Andrew Schwab latest transaction was an Informative Sell of $239.56K.
What was Andrew Schwab's most profitable transaction?
Andrew Schwab’s most profitable transaction was an Informative Sell of SKYE stock on August 22, 2025. The return on the trade was 91.40%.
What is Andrew Schwab's role in Skye Bioscience?
Andrew Schwab's role in Skye Bioscience is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.